Scilex Holding Company

Equities

SCLX

US80880W1062

Pharmaceuticals

Real-time Estimate Cboe BZX 15:33:27 2024-05-21 EDT 5-day change 1st Jan Change
1.135 USD -6.20% Intraday chart for Scilex Holding Company +42.19% -44.24%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute MT
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute MT
Scilex Issues Preliminary Q1 Sales Results for ZTlido MT
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label MT
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba MT
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed CI
Scilex Holding Company Provides Responses to Product Composition Questions Related to Its ELYXYB® Patent in Canada CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
Scilex Holding Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Midday Decliners MT
Investors Await Key Economic Data, Markets Remain Flat Ahead of Opening Bell MT
US Futures Remain Flat as Investors Await Raft of Economic Data MT
Scilex Holding Signs Underwriting Agreement for $10 Million Bought Deal Offering MT
Scilex Files $500 Million Mixed-Securities Shelf MT
Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023 CI
Scilex Files New Drug Submission for Migraine Treatment Approval in Canada MT
Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada CI
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal A High Degree of Interest in Gloperba as Liquid Colchicine Formulation Designed for Precision Dosing CI
Scilex Says US Pharmacy Chain to Stock Elyxyb MT
Scilex Holding Company Announces Major Pharmacy Initiative with the National Leading Pharmacy Chain to Stock ELYXYB® in Most of Their Stores Throughout the U.S CI
Scilex Holding Company Announces Expanded Access to Elyxyb® by the Execution of First Elyxyb® Insurance Coverage Agreement with One of the Top Three National Pbms (Pharmacy Benefit Manager) for Its Medicare Population CI
Scilex Holding Company Announces ZTlido Will Be Added as a Preferred Agent to the Medicaid Preferred Drug List in Two New States: One Midwestern and One Southern State CI
Scilex Holding Company Announces the Addition of Ztlido (Lidocaine Topical System) as A Preferred Agent to the Medicaid Preferred Drug List of the State of the State of Tennessee CI
Scilex Holding Company Reports Sales Results for the Month and Year-To-Date Ended November 30, 2023 CI
Scilex Says US FDA Successfully Completes Audit of ZTlido Plant in Japan MT
Chart Scilex Holding Company
More charts
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.21 USD
Average target price
5.5 USD
Spread / Average Target
+354.55%
Consensus
  1. Stock Market
  2. Equities
  3. SCLX Stock
  4. News Scilex Holding Company
  5. Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW